Patient-reported outcome (PRO) results from the AGO-OVAR 2.20/ENGOT-ov14/PENELOPE double-blind placebo-controlled randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum-resistant ovarian cancer (PROC)

被引：0
|
作者：
Hilbert, F. [1 ]
Gropp-Meier, M. [2 ]
Schmalfeldt, B. [2 ]
Rau, J. [3 ]
Meier, W. [4 ]
Hasenburg, A. [5 ]
Belau, A. [6 ]
Vergote, I. [7 ]
Zorr, A. [8 ]
Hils, R. [9 ]
Gerber, B. [10 ]
du Bois, A. [11 ]
Marme, F. [12 ]
Mahner, S. [13 ]
Canzler, U. [14 ]
Lueck, H. -J. [15 ]
Grischke, E. -M [16 ]
Kurzeder, C. [11 ]
机构：
[1] UKSH Campus Kiel, Klin Gynakol & Geburtshilfe, Kiel, Germany
[2] Gynakol Onkol & Brustzentrum, Oberschwabenklin, Ravensburg, Germany
[3] Univ Marburg, KKS, Marburg, Germany
[4] Evangel Krankenhaus, Frauenklin, Dusseldorf, Germany
[5] Univ Klin, Frauenklin, Freiburg, Germany
[6] Ernst Moritz Arndt Univ Greifswald, Univ Klinikum Greifswald, Klin & Poliklin Frauenheilkunde & Geburtshilfe, Greifswald, Germany
[7] Univ Hosp, Gynecol Oncol, Leuven, Belgium
[8] Klinikum Konstanz, Frauenklin, Constance, Germany
[9] HSK, Gynakol & Gynakol Onkol, Wiesbaden, Germany
[10] Klinikum Sudstadt, Univ Frauenklin & Poliklin, Rostock, Germany
[11] Kliniken Essen Mitte, Klin Gynakol Onkol, Essen, Germany
[12] Univ Frauenklin, Natl Ctr Tumorerkrankungen, Heidelberg, Germany
[13] Klinikum Univ Munchen, Klin & Poliklin Frauenheilkunde & Geburtshilfe, Munich, Germany
[14] Univ Klinikum Carl Gustav Carus, Klin & Poliklin Frauenheilkunde & Geburtshilfe, Dresden, Germany
[15] Gynakol Onkol Praxis Pelikanpl, Hannover, Germany
[16] Univ Klinikum Tubingen, Univ Frauenklin, Tubingen, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2016年 / 39卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
0087
引用
收藏
页码：138 / 138
页数：1
相关论文
共 46 条
  • [41] Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
    Garassino, Marina C.
    Gadgeel, Shirish
    Esteban, Emilio
    Felip, Enriqueta
    Speranza, Giovanna
    Domine, Manuel
    Hochmair, Maximilian
    Powell, Steve
    Cheng, Susanna Yee-Shan
    Bischoff, Helge G.
    Peled, Nir
    Reck, Martin
    Hui, Rina
    Garon, Edward B.
    Boyer, Michael
    Wei, Ziwen
    Burke, Thomas
    Pietanza, M. Catherine
    Rodriguez-Abreu, Delvys
    LANCET ONCOLOGY, 2020, 21 (03): : 387 - 397
  • [42] Effects of Trilaciclib on Chemotherapy-Induced Myelosuppression and Patient-Reported Outcomes in Patients with Extensive-Stage Small Cell Lung Cancer: Pooled Results from Three Phase II Randomized, Double-Blind, Placebo-Controlled Studies
    Weiss, Jared
    Goldschmidt, Jerome
    Andric, Zoran
    Dragnev, Konstantin H.
    Gwaltney, Chad
    Skaltsa, Konstantina
    Pritchett, Yili
    Antal, Joyce M.
    Morris, Shannon R.
    Daniel, Davey
    CLINICAL LUNG CANCER, 2021, 22 (05) : 449 - 460
  • [43] A randomized, double-blind, placebo-controlled, multicenter phase II study to compare the efficacy and safety of sorafenib added to standard treatment with topotecan to standard treatment alone in patients with platinum-resistant recurrent ovarian cancer (TRIAS): Results of a NOGGO-AGO intergroup pilot-study.
    El Khalfaoui, K.
    Mahner, S.
    Richter, R.
    Hilpert, F.
    Lorenz, R.
    Harter, P.
    Klare, P.
    Wagner, U. A. G.
    Chekerov, R.
    Sehouli, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [44] Atezolizumab (atezo) combined with platinum-based chemotherapy (CT) and maintenance niraparib for recurrent ovarian cancer (rOC) with a platinum-free interval (TFIp) >6 months: Primary analysis of the double-blind placebo (pbo)controlled ENGOT-Ov41/GEICO 69-O/ANITA phase III trial
    Martin, A. Gonzalez
    Perez, M. J. Rubio
    Heitz, F.
    Christensen, R. D.
    Colombo, N.
    Van Gorp, T.
    Oaknin, A.
    Leary, A.
    Garcia, L. Gaba
    Lebreton, C.
    Gonzalez, L. M. De Sande
    Marin, M. Romeo
    Redondo, A.
    Ginesta, M. P. Barretina
    Fidalgo, J. A. Perez
    Bertran, A. Santaballa
    Bermejo-Perez, M. J.
    Bruchim, I.
    Ray-Coquard, I. L.
    Selle, F.
    ANNALS OF ONCOLOGY, 2023, 34 : S1278 - S1279
  • [45] Patient-reported outcomes from the phase III, randomized, double-blind, placebo-controlled ENGOT-cx11/GOG-3047/ KEYNOTE-A18 Study of pembrolizumab plus concurrent chemoradiotherapy among patients with high-risk, locally advanced cervical cancer
    Randall, Leslie
    Sukhin, Vladyslav
    Colombo, Nicoletta
    Korach, Jacob
    Matsumoto, Takashi
    Lalondrelle, Susan
    Vizkeleti, Julia
    Samouelian, Vanessa
    Salani, Ritu
    Salman, Pamela
    Nogueira-Rodrigues, Angelica
    Ayhan, Ali
    Frentzas, Sophia
    Cueva, Juan
    Kim, Yong-Man
    Petru, Edgar
    Milla, Dency Pilar
    Sehouli, Jalid
    Saevets, Valeriya
    Yamada, Karin
    Li, Kan
    Szamreta, Elizabeth
    Nguyen, Allison Martin
    Pignata, Sandro
    Lorusso, Domenica
    GYNECOLOGIC ONCOLOGY, 2024, 190 : S9 - S9
  • [46] ATHENA (GOG-3020/ENGOT-OV45; EUDRACT 2017-004557-17; NCT03522246): A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY OF THE POLY(ADP-RIBOSE) POLYMERASE (PARP) INHIBITOR RUCAPARIB + THE PD-1 INHIBITOR NIVOLUMAB FOLLOWING FRONTLINE PLATINUM-BASED CHEMOTHERAPY IN OVARIAN CANCER (OC)
    Christopoulou, A.
    Marme, F.
    Oaknin, A.
    Lorusso, D.
    Safra, T.
    Lindahl, G.
    Chudecka-Glaz, A.
    Ciuleanu, T.
    Collins, D. C.
    Demirkiran, F.
    Lifrenko, I.
    Van Gorp, T.
    Coleman, R. L.
    Fujiwara, K.
    Oza, A. M.
    Westin, S. N.
    O'Malley, D. M.
    Herzog, T. J.
    Eskander, R.
    Wilson, M.
    Argire, S.
    Grechko, N.
    McNeish, I. A.
    Monk, B. J.
    Kristeleit, R. S.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 : A130 - A131
12345